Pain management testing services    

Comprehensive testing to mitigate risks

The use of controlled substances to manage pain is widely accepted by health care professionals, but these prescriptions correlate with an increased risk for drug abuse and overdose. Because as many as one in four patients on long-term, controlled substance therapy struggles with addiction, objective measures are needed to identify recent drug use and evaluate for misuse.

Our patient-centric approach to controlled substance monitoring is backed by more than 150 years of medical knowledge and developed by an award-winning team of pain medicine, primary care, and addiction experts who work collaboratively with the Clinical and Forensic Toxicology Laboratory at Mayo Clinic. Our tests are based on practice guidelines developed by the American Association for Clinical Chemistry Academy, and provide clinicians with assistance to ensure patients who receive controlled substance therapy remain within regulatory parameters.

By the numbers

200+

lab-developed therapeutic tests available

24/7

client support

95

active clinical studies for pain medicine

Full-spectrum approach to pain management testing

  • Controlled substance monitoring
    • Specimen validity testing
    • Targeted mass spectrometry screening profiles
    • Select immunoassay screening
    • Confirmatory testing with quantification
    • Result interpretations
  • Pharmacogenomic testing
  • Therapeutic drug monitoring
  • Clinical research
  • Expert support and education

Access the industry’s leading evidence-based test menu

Our liquid chromatography-tandem mass spectrometry, high-resolution accurate mass (LC-MS/MS HRAM) screens, and confirmatory testing for identification and monitoring controlled substances are available based on the needs of your patients and laboratory. 

Routine monitoring

CSMPU  | Controlled Substance Monitoring Profile, 20 Drug Classes, Urine

  • Identifies drug use involving amphetamines, barbiturates, benzodiazepines, cocaine, opioids, phencyclidine (PCP) and carboxy-tetrahydrocannabinol (COOH-THC)
  • Includes specimen validity testing
  • Results reported with interpretative comments

Please note: If the limited immunoassay screen is positive in this profile (Mayo ID: CSMPU), confirmation with quantification of presumptive positives for barbiturates, cocaine and metabolites, and/or tetrahydrocannabinol metabolite will be performed at an additional charge. If the quantification of presumptive positive results is not required, refer to Controlled Substance Monitoring Hybrid Drug Profile, High-Resolution Mass Spectrometry, and Immunoassay Screen, Random, Urine (Mayo ID: CSMHU)

Comprehensive monitoring

CSMEU  | Controlled Substance Monitoring Enhanced Profile, 21 Drug Classes, Urine

  • Identifies drug use involving alcohol**, amphetamines, barbiturates, benzodiazepines, cocaine, opioids, PCP, and COOH-THC
  • Includes specimen validity testing
  • Results reported with interpretative comments

Targeted screening

CSMTU  | Controlled Substance Monitoring Targeted Profile, 17 Drug Classes, Urine

  • Identifies drug use involving amphetamines, benzodiazepines, opioids, and PCP where immunoassays are not adequate
  • Includes specimen validity testing
  • Results reported with interpretative comments

TOSU  | Targeted Opioid Screen, 10 Drug Classes, Urine

  • Uses high-resolution accurate mass spectrometry to identify 33 different opioids and metabolites (i.e.,buprenorphine, codeine, fentanyl, heroin, hydrocodone, hydromorphone, methadone, morphine, naloxone, oxycodone, tapentadol, tramadol) where immunoassays are not adequate
  • Detects spiked specimens
  • Results reported with interpretative comments

TBSU  | Targeted Benzodiazepine Screen, 3 Drug Classes, Urine

  • Uses high-resolution accurate mass spectrometry to identify 27 different benzodiazepines and metabolites (i.e., clobazam, zolpidem and all commonly prescribed benzodiazepines) where immunoassays are not adequate
  • Detects spiked specimens
  • Results reported with interpretative comments

TSPU  | Targeted Stimulant Screen, 4 Drug Classes, Urine

  • Uses high-resolution accurate mass spectrometry to identify 11 different stimulants and metabolites (i.e., amphetamines, methylphenidate, ritlanic acid, 3,4-Methylenedioxymethamphetamine [MDMA], PCP) where immunoassays are not adequate
  • Detects spiked specimens
  • Results reported with interpretative comments

*To better meet the needs of our clients’, this profile is available with the quantification of presumptive positive results (Mayo Test ID: CSMPU) or without (Mayo Test ID: CSMHU) for the drug classes screened by immunoassay (i.e., barbiturates, cocaine, and THC).
**Ethyl glucuronide (EtG) and ethyl sulfate (EtS) are direct biomarkers of ethanol and are detectable in urine for up to five days following alcohol consumption. EtG/EtS results should be interpreted in the context of all available clinical and behavioral information.

Learn more about how to order these tests at your institution.

Resources

Mayo Clinic Pain Medicine CME Opportunities  

Hot Topic: Opioid Targeted Screening at Mayo Clinic Laboratories

Hot Topic: Interpretation of qualitative and quantitative urine opiate tests for pain management patients

Pain Medicine at Mayo Clinic

The origins of the modern pain clinic at the Mayo Clinic

Opioid Risk Tool

CDC Clinical Guideline for Prescribing Opioids for Chronic Pain

CDC Opioid Data Analysis and Resources